Discover how HYQVIA's expanded indications significantly enhance treatment options for patients managing chronic conditions.
By Marianna Herrera - RN, BSN, IgCN, Clinical Nurse Educator II - May 23, 2025
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration was first FDA-approved in 2014 for primary immunodeficiency (PIDD) in adults. In 2023, HYQVIA® received expanded FDA-approval in PIDD to include pediatric patients aged 2-16. In 2024 HYQVIA® received FDA-approval for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
CIDP is rare and believed to be an autoimmune disorder. Symptoms include weakness usually beginning in the legs and then arms. There may be numbness or tingling starting in the feet or hands (stocking-glove pattern) and then traveling upward. The symptoms start and progress slowly over months and even years. CIDP can improve and then worsen again, with or without medication. Adult patients who have been on stable doses of IVIG may transition to HYQVIA® for maintenance of CIDP.
HYQVIA® is for subcutaneous use only. Unlike all other commercially available subcutaneous immunoglobulin (SCIG) products, HYQVIA® is additionally packaged with recombinant hyaluronidase (HY) and is referred to as “facilitated SCIG” (fSCIG). HY temporarily increases the permeability of SC tissue, allowing large volumes of immunoglobulin 10% to be administered. fSCIG volumes administered are much greater than traditional SCIG volumes and more comparable to volumes administered intravenously. HYQVIA® is usually infused every 3-4 weeks by a health care provider or self-administered after proper training. Nufactor will provide educational resources to infusion nurses to help patients self-administer successfully. Patients can usually become independent after 3-5 teach and train visits. Nufactor will individually tailor to the needs of each patient. Nurses are provided with this checklist to ensure patients demonstrate competency in self-administration skills: Nufactor SCIG-FSCIG Infusion Checklist
HYQVIA® FDA approval for pediatric use for PIDD patients and maintenance use in adult patients with CIDP marks a significant advancement in treatment options for patients managing their chronic conditions. These milestones not only provide more options for individualized care but also bring hope for both the PIDD and CIDP communities.
References
